Skip to content

Infectious Disease Implementation Research

The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.

The Infectious Disease Implementation Research team is developing and implementing better ways to observe and evaluate the effectiveness of public health programs, including optimising treatment for both acute and complex diseases and  exploring new strategies through disease modelling and analytics - providing real-world results that are immediately applicable.

The team uses a range of methods to conduct their research, including pragmatic and adaptive clinical trials, observational comparative effectiveness studies and data linkage studies, causal network and transmission modelling and learning health systems research.

Focusing on common and serious childhood infections such as gastroenteritis, serious bacterial infections and cystic fibrosis exacerbations, the Implementation Research team are looking at new and innovative clinical trial methods and analytic approaches for evaluating treatments. This includes examining their effectiveness by embedding research in the clinical settings they are intended to be used, and working on projects to gauge efficacy of new and existing preventions and treatments in a way that has never been done before in Australia.

Collaborating widely, the team works with clinicians, policy makers, epidemiologists, statisticians and importantly, community members, to help ensure their research is efficient, sustainable and responsive to clinical, community and policy needs. The team also work in close collaboration with other research groups around Australia, including the University of Sydney’s Health and Clinical Analytics Team, particularly to support many studies that are underway at sites outside of Western Australia.

Team Highlights

In 2019, the Implementation Reseatch team were successful in securing major funding for:

  • Randomised controlled trial of mixed whole-cell/acellular pertussis vaccination versus acellular-only vaccination of infants (GNT1158722, NHMRC project grant, 2019-2023, $3.9million)
  • Adaptive Trial of Messaging to Improve Vaccine Coverage (AuTOMATIC), (Ramaciotti Health investment grant, 2020-22, $280,000)
  • Collaborative project 'Better health through better trials: a national network to develop and implement innovative clinical trials methodology'. (GNT1171422, NHMRC Centres of Research Excellence, 2019-2024, $2.4million)

The Implementation Research team shared its ideas and results to several audiences across a range of mediums, including:

  • providing educational seminars to students, researchers and clinical trialists throughout Australia
  • launching the Adaptive Health Intelligence website to optimise further collaborative opportunities
  • holding consumer workshops for individuals living with cystic fibrosis and hepatitis C.

Team leader

Professor Tom Snelling
Professor Tom Snelling

BMBS DTMH GDipClinEpid PhD FRACP

Head, Infectious Disease Implementation Research

Team members (15)

Danielle Darragh

Danielle Darragh

Program Manager, Infectious Disease Implementation Research

Julie Marsh

Julie Marsh

Biostatistical Lead

Michael Dymock

Michael Dymock

Biostatistician, PhD Student

Nelly Newall

Nelly Newall

Clinical Trial Co-ordinator

Jessica Ramsay

Jessica Ramsay

Clinical Research Coordinator – Casual

Reena D’Souza

Reena D’Souza

Project Manager

Kylie Rogers

Kylie Rogers

Data Manager

Mitch Messer

Mitch Messer

Consumer Advisor

Charlie McLeod

Charlie McLeod

Clinical Research Officer

Evelyn Tay

Evelyn Tay

Biostatistician

Ariel Mace

Ariel Mace

PhD Student

Carly McCallum

Carly McCallum

Clinical Research Manager

Ada Parry

Ada Parry

Cultural Advisor

Edward Pan

Edward Pan

Statistical Programmer

George Salama

George Salama

Clinical Trial Coordinator

Infectious Disease Implementation Research

Resources

Reports and Findings

Reports and Findings

BEAT-BK: An Adaptive, Randomized Controlled Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Kidney-pancreas Transplantation Recipients (BEAT-BK) Study Protocol

BK polyomavirus (BKPyV) is a common opportunistic infection in kidney transplant recipients, typically reactivating in the context of immunosuppression. Although asymptomatic in immunocompetent individuals, reactivation in transplant recipients can cause BKPyV-associated nephropathy (BKPyVAN), a leading cause of graft dysfunction and loss. BKPyV viremia affects approximately 10%-15% of transplant recipients, and once BKPyVAN is established, the risk of graft failure can exceed 50%.

A Pragmatic Bayesian Adaptive Trial Design Based on the Value of Information: The Value-Driven Adaptive Design

Clinical trial designs are typically narrowly focused on error control in hypothesis testing, but this approach is inadequate in many contexts, particularly when a decision maker intends to, or must, consider multiple relevant clinical and health economic outcomes under uncertainty. Value-of-information (VoI) metrics can be used to estimate the monetary value of data collection to the decision maker. 

The AuTOMATIC trial: a multicentre digitally-automated, Bayesian, adaptive, parallel, factorial randomised controlled trial of SMS reminders for childhood vaccination

The estimated effectiveness of SMS (short message service) reminders for improving childhood vaccine coverage and timeliness has varied in previous studies. The observed heterogeneity in effectiveness may be explained in part by variation in reminder content or timing of the reminder relative to the vaccine schedule date. We sought to evaluate the effectiveness of a range of SMS reminders of varied content and timing for improving on-time childhood vaccination.

Burden and Experiences of Head Lice Infestation Among Children in Western Australia

Head lice is an ectoparasitic skin infection commonly seen in primary school-aged children. In remote Australia, where rates of other skin infections and downstream sequelae are endemic, the rate of head lice infestation is unknown.

Show all